Age
Item
male or female patients, from 18 to 65 years of age at visit 1
boolean
C0001779 (UMLS CUI [1])
Able to communicate Study Coordinator | Participation Testing Cognitive
Item
patients must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.
boolean
C2364293 (UMLS CUI [1,1])
C1710220 (UMLS CUI [1,2])
C0679823 (UMLS CUI [2,1])
C0039593 (UMLS CUI [2,2])
C1516691 (UMLS CUI [2,3])
Protocol Compliance
Item
patients must agree to cooperate with all tests and examinations required by the protocol. they must be willing to comply fully with treatment
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
patient must understand the nature of the study and must sign an informed consent document.
boolean
C0021430 (UMLS CUI [1])
Able to speak Cantonese Chinese dialect
Item
patients must be cantonese speaking han chinese
boolean
C0564215 (UMLS CUI [1,1])
C0682397 (UMLS CUI [1,2])
Schizophrenia | Schizoaffective Disorder | psychosis; schizophreniform
Item
patients must be diagnosed, according to the scid for dsm-iv, with schizophrenia, schizoaffective disorder or schizophreniform psychosis.
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0865304 (UMLS CUI [3])
Antipsychotic drug therapy Good therapeutic response | Clinical Global Impression Questionnaire | Improvement rating scale | Conceptual Disorganization | Unusual Thought Content | Delusions | Hallucinatory Behavior | Suspicious behavior | Positive and negative syndrome scale
Item
patients must have good response to anti-psychotic treatment by achieving a rating of 2 or below in clinical global impression scale (cgi) severity of illness; a rating of 4 or below in improvement scale, and a rating of 3 or below in (conceptual disorganization, unusual thought content), a rating of 2 or below in (delusion, hallucinatory behavior) and a rating of 4 or below in (suspiciousness) of positive and negative syndrome scale (panss) for at least 8 weeks
boolean
C1319421 (UMLS CUI [1,1])
C0184785 (UMLS CUI [1,2])
C3639708 (UMLS CUI [2])
C2986411 (UMLS CUI [3,1])
C0681889 (UMLS CUI [3,2])
C3639359 (UMLS CUI [4])
C3639370 (UMLS CUI [5])
C0011253 (UMLS CUI [6])
C3639367 (UMLS CUI [7])
C0233519 (UMLS CUI [8])
C0451383 (UMLS CUI [9])
Pregnancy | Breast Feeding
Item
female patients who are either pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Clozapine
Item
patients previously on clozapine should be excluded from the study
boolean
C0009079 (UMLS CUI [1])
Illness Significant | Seizures
Item
significant medical illnesses including seizures.
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0036572 (UMLS CUI [2])
Substance Use Disorders | Substance Dependence
Item
dsm-iv substance (alcohol or other drugs) abuse or dependence within the past 3 months.
boolean
C0038586 (UMLS CUI [1])
C0038580 (UMLS CUI [2])
At risk for suicide Serious
Item
judged clinically to be at serious suicidal risk.
boolean
C0563664 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Injection of depot antipsychotic agent
Item
treatment with an injectable depot neuroleptic within less than one of the patient's dosing intervals between depot neuroleptic injections prior to study entry.
boolean
C2585377 (UMLS CUI [1])